BC
UTHR icon

Brahman Capital’s United Therapeutics UTHR Stock Holding History

Brahman Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$2.37M Buy
10,473
+1,308
+14% +$301K 0.86% 14
2023
Q2 		$2.02M Sell
9,165
-11,736
-56% -$2.6M 0.55% 17
2023
Q1 		$4.68M Sell
20,901
-19,933
-49% -$4.91M 0.58% 16
2022
Q4 		$11.4M Sell
40,834
-3,683
-8% -$930K 1.57% 14
2022
Q3 		$9.32M Buy
44,517
+17,359
+64% +$3.88M 1.31% 15
2022
Q2 		$6.4M Sell
27,158
-152
-0.6% -$30.9K 0.76% 18
2022
Q1 		$4.9M Sell
27,310
-93,172
-77% -$17.7M 0.43% 20
2021
Q4 		$26M Sell
120,482
-50,472
-30% -$9.91M 1.9% 18
2021
Q3 		$31.6M Sell
170,954
-75,793
-31% -$14.9M 2.31% 17
2021
Q2 		$44.3M Buy
246,747
+253
+0.1% +$48.2K 3.27% 16
2021
Q1 		$41.2M Buy
246,494
+201,969
+454% +$33.7M 3.49% 13
2020
Q4 		$6.76M Buy
44,525
+20,121
+82% +$2.64M 0.59% 19
2020
Q3 		$2.46M Buy
24,404
+13,700
+128% +$1.5M 0.24% 21
2020
Q2 		$1.29M Buy
+10,704
New +$1.2M 0.13% 25

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Brahman Capital's UTHR Position: Q3 2023 in Review

Brahman Capital increased its United Therapeutics (UTHR) stake by 14% in Q3 2023, buying an estimated $301K and bringing the position to 10,473 shares worth $2.37M. The position accounts for 0.86% of the portfolio, ranked #14.

Brahman Capital first reported a position in UTHR in Q2 2020 and has held it in 14 quarters since. The position peaked at $44.3M in Q2 2021. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

  • Brahman Capital held 10,473 shares of United Therapeutics worth $2.37M as of Q3 2023.
  • Brahman Capital bought 1,308 United Therapeutics shares in Q3 2023, an estimated $301K.
  • United Therapeutics made up 0.86% of Brahman Capital's portfolio in Q3 2023, its #14 holding.
  • Brahman Capital first reported a position in United Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Brahman Capital's United Therapeutics position peaked at $44.3M in Q2 2021.
  • 508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Brahman Capital's 13F filing for Q3 2023, filed 14 Nov 2023.